The Technical AnalystExchange: TSX Industry: Biotechnology
Eupraxia Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.91% $3.94
America/New_York / 3 mai 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 140.35 mill |
| EPS: | -1.170 |
| P/E: | -3.37 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 35.62 mill |
| Avg Daily Volume: | 0.0669 mill |
| RATING 2024-05-03 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.37 | sector: PE 21.44 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -3.37 | industry: PE -18.01 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.485 (-87.68%) $-3.45 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.60 - 4.28 ( +/- 8.55%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.94 (5.91% ) |
| Volume | 0.0215 mill |
| Avg. Vol. | 0.0669 mill |
| % of Avg. Vol | 32.12 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EPRX.TO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EPRX.TO
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.